Core Viewpoint - The beauty industry is currently experiencing a "ingredient dispute" focusing on two key ingredients: hyaluronic acid and recombinant collagen, which has expanded to discussions on business strategies of leading beauty companies, the ecological environment of the industry, and the public sentiment in the capital market [2][3] Summary by Sections Hyaluronic Acid - Hyaluronic acid, known scientifically as hyaluronic acid (HA), is a crucial component of human tissue, comprising about 50% of the total amount in the skin, and is recognized for its powerful moisturizing, soothing, repairing, and anti-aging properties [5][6] - Historically, hyaluronic acid was monopolized by foreign companies in the 1980s, making it expensive and inaccessible to the Chinese market. Furuida Biotech broke this monopoly by developing a microbial fermentation method, reducing the cost of hyaluronic acid by 90% [6][8] - Furuida has established a complete industrial chain centered around hyaluronic acid, covering raw materials, pharmaceuticals, cosmetics, functional foods, and medical devices, and has created several well-known beauty brands [8][10] Recombinant Collagen - The recombinant collagen market in China has grown from 1.5 billion yuan in 2017 to 10.8 billion yuan in 2021, with a projected compound annual growth rate of 42.4% until 2027 [11] - Recombinant collagen is seen as a next-generation regenerative medicine material, offering advantages such as no viral risk and high biocompatibility, and is expected to complement hyaluronic acid in skincare [13][14] Furuida's Strategic Moves - Furuida has recognized the complementary relationship between hyaluronic acid and recombinant collagen, launching its first medical beauty brand, Kemi, in December 2023, and investing in a production line for recombinant collagen [14][16] - The company has achieved significant milestones in recombinant collagen research, including obtaining medical-grade material qualifications and developing various types of collagen with multiple patents [16][18] Market Performance - Furuida's cosmetics sales revenue reached 2.475 billion yuan in 2024, with a gross margin of 62.57%, indicating a stable performance in its main business segment [17][18] - The dual focus on hyaluronic acid and collagen has led to rapid growth for its brands, with the Yilian brand achieving 963 million yuan in revenue in 2024, a year-on-year increase of 12.36% [20] Future Outlook - Both hyaluronic acid and recombinant collagen have significant growth potential, with recent research highlighting the extracellular matrix (ECM) as a new frontier in anti-aging studies [20][21] - Furuida's innovative approach, including the development of a breakthrough ingredient that accurately restores ECM protein composition, is redefining the application boundaries of collagen [21][22] - The success of hyaluronic acid represents a model for the Chinese beauty industry, showcasing the potential for multiple "hyaluronic acid effects" to drive industry growth and global competitiveness [22]

Core Viewpoint - Furuida has established itself as a leader in the hyaluronic acid industry in China, breaking foreign monopolies and achieving significant success across various sectors including pharmaceuticals, cosmetics, and food, with over 70% of global hyaluronic acid raw materials sourced from China [1][2][3]. Group 1: Hyaluronic Acid Industry - Furuida pioneered the industrial-scale production of hyaluronic acid through microbial fermentation, reducing costs by 90% compared to traditional animal extraction methods [2]. - The company has developed a complete industrial chain around hyaluronic acid, including raw materials, pharmaceuticals, cosmetics, functional foods, and medical devices, supported by multiple national and provincial research platforms [3][4]. - Furuida's innovative products, such as various patented hyaluronic acid formulations, have made it a dominant player in the cosmetics and medical aesthetics sectors, with a notable market presence in China [4]. Group 2: Collagen and Future Growth - Furuida is expanding into the recombinant collagen market, launching its first medical aesthetics brand, Kemi, and investing significantly in production capabilities [5][6]. - The company emphasizes the complementary relationship between hyaluronic acid and collagen, positioning the combination as a solution for long-lasting anti-aging needs [6][7]. - Furuida has rapidly advanced its recombinant collagen technology, achieving medical-grade certifications and developing multiple collagen products, with ongoing research into high-value medical devices [7][8]. Group 3: Innovation and Market Position - Furuida's growth story exemplifies how technological innovation can reshape industry dynamics, transitioning from a focus on hyaluronic acid to establishing a foothold in the recombinant collagen sector [8]. - The company aims to leverage its technological advancements and ecosystem approach to navigate the global health and beauty market, setting a precedent for other Chinese enterprises [8].

丨证券研究报告丨 公司研究丨点评报告丨福瑞达（600223.SH） [Table_Title] 福瑞达 2025 年一季报点评：颐莲增势良好，药 品及原料业务企稳 报告要点 [Table_Summary] 公司发布 2025 年一季报。2025Q1，公司实现营收 8.76 亿元，同比下滑 1.63%；归母净利润 0.51 亿元，同比下滑 14.1%；扣非归母净利润 0.47 亿元，同比下滑 9.67%。 分析师及联系人 [Table_Author] SAC：S0490514080004 SAC：S0490520080019 SAC：S0490524110002 SFC：BUV258 请阅读最后评级说明和重要声明 %% %% %% %% research.95579.com 1 李锦 罗祎 秦意昂 曾维朵 福瑞达（600223.SH） cjzqdt11111 [Table_Title 福瑞达 20252]年一季报点评：颐莲增势良好，药 品及原料业务企稳 [Table_Summary2] 事件描述 公司发布 2025 年一季报。2025Q1，公司实现营收 8.76 亿元，同比下滑 1.63%；归母净利润 0.51 ...

Group 1 - The recombinant protein concept sector rose by 2.52%, ranking second among concept sectors, with 30 stocks increasing in value [1][2] - Notable gainers included Sangon Biotech, which hit the daily limit with a 20% increase, and other significant performers such as Sai Sheng Pharmaceutical, Jie Ya Co., and Jinbo Bio, which rose by 16.37%, 9.31%, and 9.17% respectively [1][2] - The sector experienced a net inflow of 221 million yuan from main funds, with 23 stocks receiving net inflows, and 8 stocks exceeding 10 million yuan in net inflow [2][3] Group 2 - Leading the net inflow was Xilong Scientific, which saw a net inflow of 242 million yuan, followed by Rejuve Pharmaceutical and Zexin Pharmaceutical with net inflows of 37.78 million yuan and 32.48 million yuan respectively [2][3] - The top three stocks by net inflow ratio were Xilong Scientific at 20.85%, Zexin Pharmaceutical at 8.53%, and Chengdu Xian Dao at 7.96% [3][4] - Stocks with notable declines included Furuida, Zhongyuan Xiehe, and Wanmei Biological, which fell by 2.25%, 1.92%, and 1.80% respectively [1][5]

Market Overview - The Shanghai Composite Index fell by 0.40% on May 16, with 15 industries experiencing gains, led by the automotive and machinery sectors, which rose by 1.91% and 0.83% respectively [1] - The beauty and personal care sector had the largest decline, dropping by 1.31%, followed by the non-bank financial sector, which fell by 1.21% [1] Capital Flow Analysis - The net inflow of capital in the two markets was 307 million yuan, with 14 industries seeing net inflows. The automotive sector led with a net inflow of 4.616 billion yuan, while the basic chemical industry had a net inflow of 1.981 billion yuan and a daily increase of 0.60% [1] - Conversely, 17 industries experienced net outflows, with the non-bank financial sector seeing the largest outflow of 1.925 billion yuan, followed by the transportation sector with a net outflow of 1.250 billion yuan [1] Beauty and Personal Care Sector - The beauty and personal care sector saw a decline of 1.31% with a net outflow of 294 million yuan. Out of 31 stocks in this sector, 11 rose while 20 fell [2] - The stocks with the highest net inflow included Qingdao Kingking with 50.67 million yuan, followed by Zhongshun Jierou and Yiyi Co., with net inflows of 20.55 million yuan and 9.64 million yuan respectively [2] - Notable stocks with significant net outflows included Furuida with 151 million yuan, Aimeike with 49.19 million yuan, and Qingsong Co. with 38.32 million yuan [2] Individual Stock Performance - The top stocks in the beauty and personal care sector based on capital flow include: - Furuida: -3.82% with a net outflow of 150.98 million yuan [3] - Aimeike: -2.06% with a net outflow of 49.19 million yuan [3] - Qingsong Co.: -7.34% with a net outflow of 38.32 million yuan [3] - Other notable performers include: - Qingdao Kingking: +1.89% with a net inflow of 50.67 million yuan [3] - Zhongshun Jierou: +0.87% with a net inflow of 20.55 million yuan [3]

（原标题：美容护理行业5月15日资金流向日报） 沪指5月15日下跌0.68%，申万所属行业中，今日上涨的有4个，涨幅居前的行业为美容护理、煤炭，涨 幅分别为3.68%、0.42%。美容护理行业位居今日涨幅榜首位。跌幅居前的行业为计算机、通信，跌幅 分别为2.97%、2.45%。 美容护理行业今日上涨3.68%，全天主力资金净流入3.86亿元，该行业所属的个股共31只，今日上涨的 有28只，涨停的有8只；下跌的有3只。以资金流向数据进行统计，该行业资金净流入的个股有23只，其 中，净流入资金超3000万元的有9只，净流入资金居首的是福瑞达，今日净流入资金1.11亿元，紧随其 后的是青松股份、洁雅股份，净流入资金分别为6854.51万元、4824.24万元。美容护理行业资金净流出 个股中，净流出资金居前的有青岛金王、稳健医疗、上海家化，净流出资金分别为1.72亿元、1446.11万 元、1146.58万元。（数据宝） | 代码 | 简称 | 今日涨跌幅（%） | 今日换手率（%） | 主力资金流量（万元） | | --- | --- | --- | --- | --- | | 600223 | 福瑞达 | 10. ...

Market Overview - The market experienced a volume contraction with the ChiNext index dropping nearly 2% by the end of the day. The synthetic biology concept stocks surged, with companies like Chuaning Biological, Jieya Co., and Meinong Biological hitting the daily limit. The shipping sector saw a rise and subsequent fall, with Ningbo Shipping, Ningbo Ocean, and Lianyungang achieving three consecutive limits. Consumer stocks in food, apparel, and beauty care were active, with Xiwang Food, Lafang Cosmetics, and Fengzhu Textile also hitting the daily limit. Conversely, the military industry faced adjustments, with Tianjian Technology nearing a limit down, and computing power concept stocks weakened, with Hongjing Technology dropping nearly 10%. Overall, over 3,800 stocks in the Shanghai and Shenzhen markets declined, with a total transaction volume of 1.19 trillion [1]. Hot Topics Health Products - Kolun Pharmaceutical's advertisement for ergothioneine capsules has sparked significant discussion, with Chairman Liu Gexin personally endorsing the product. Ergothioneine is a natural small molecule derived from histidine thiourea, found in microbial cells and plants. It cannot be synthesized by the human body and must be obtained through diet, with mushrooms being a key source. Sales of oral beauty products containing ergothioneine on a major e-commerce platform surged by 60 times year-on-year in the first half of 2024 [4][5]. Shipping - The shipping sector remained active, with Ningbo Ocean and Lianyungang achieving three consecutive limits. Following trade negotiations between China and the U.S., container shipping bookings from China to the U.S. surged nearly 300%, with the average booking volume for 20-foot standard containers skyrocketing to 21,530, up from 5,709 a week prior. Goldman Sachs anticipates a significant increase in Chinese exports over the next 90 days due to a tariff suspension [6][8]. Consumer Sector - The consumer sector was lively, with stocks like Marubi, Dengkang Dental, and Baiyang hitting the daily limit. The Tmall 618 promotion commenced, with the first hour's GMV for popular beauty products increasing over 10% year-on-year. Additionally, the price of tilapia has risen to 4.5 yuan per pound, with China being a major producer and exporter of tilapia, producing over 1.6 million tons annually, with about a quarter exported to the U.S. [9][10]. Stock Performance - Notable stocks in the health products sector include: - Jiaoda Aongli (600530.SS) with a price of 7.50, up 9.97%, and a market cap of 5.812 billion - Lafang Cosmetics with a price of 21.97, up 10.02%, and a market cap of 4.948 billion - Chuaning Biological with a price of 14.02, up 20.03%, and a market cap of 8.635 billion [5][10]. - In the shipping sector: - Ningbo Ocean (601022.SS) at 11.12, up 9.99%, with a market cap of 2.765 billion - Lianyungang (601008.SS) at 6.77, up 10.08%, with a market cap of 8.399 billion [7][10]. - In the consumer sector: - Zhejiang Yongqiang (002489.SZ) at 4.07, up 10.00%, with a market cap of 7.786 billion - Marubi (603983.SS) at 52.53, up 10.01%, with a market cap of 21.065 billion [10].

Group 1 - The A-share cosmetics sector experienced a significant rise in the afternoon, with Huaye Fragrance hitting the daily limit up [1] - Furuida, Lafang Home, and Bawi Co. previously reached their daily limit, while Qingsong Co. surged over 10% [1] - Other companies such as Shanghai Jahwa, Proya, Jiaheng Home, Jinsong New Materials, and Beitaini also saw increases [1]

Market Overview - On May 15, A-shares experienced a decline, with the Shanghai Composite Index falling by 0.42% to 3389.75 points, the Shenzhen Component Index down by 1.12%, and the ChiNext Index decreasing by 1.35% [1][2] - The total trading volume for A-shares reached 765.59 billion yuan [1] Economic Indicators - The People's Bank of China conducted a 645 billion yuan reverse repurchase operation with a fixed interest rate of 1.40%, resulting in a net withdrawal of 219.1 billion yuan for the day [2] Industry Insights - The China-U.S. Economic and Trade Cooperation Exchange Conference was successfully held in Washington, emphasizing the long-standing and mutually beneficial trade relationship between the two countries [3] - Despite current challenges, there is significant potential for future cooperation, particularly in maintaining global supply chain stability [3] Sector Performance - Port and shipping stocks saw a resurgence, with notable increases in shares of Nanjing Port, Lianyungang, and Ningbo Maritime [3] - Beauty and personal care stocks also performed well, with companies like Jieya Co. and Furuida reaching their daily limit up [3] - Synthetic biology stocks were active, with companies such as Chuaning Biological, Jindawei, and Hainan Haiya hitting their daily limit up [3] Sector Trends - The synthetic biology sector is expected to grow, with significant applications in various fields, although it currently holds a limited share in the overall chemical market [4] - The international landscape for synthetic biology is primarily dominated by the U.S. and Europe, which may influence domestic policy and development [4] Company Profiles 1. **Chuaning Biological**: Focuses on synthetic biology with products in production and plans to expand into high-value products and efficient strains by 2025 [7] 2. **Jieya Co.**: A leading manufacturer of wet wipes, shifting focus towards wet toilet paper and expanding into medical devices and cosmetics [8] 3. **Furuida**: Aims to build a comprehensive health industry chain, leveraging R&D strengths in cosmetics and pharmaceuticals [8] 4. **Jindawei**: Positioned as a leader in the health supplement market, benefiting from market expansion and stable financial performance [8]

Core Viewpoint - The company, Furuida, reported a strong performance in Q1 2025, with significant growth in its core brand Yilian and a focus on brand enhancement and technological innovation amidst a volatile external environment [1][2]. Group 1: Financial Performance - In Q1 2025, the company achieved a revenue of 876 million yuan and a net profit of 50.71 million yuan, aligning with market expectations [2]. - The cosmetics segment generated a revenue of 526 million yuan with a gross margin of 61.1%, indicating strong profitability [2][3]. Group 2: Brand and Product Development - The Yilian brand recorded a revenue of 250 million yuan, a 25% year-on-year increase, with spray product sales surging by 69% [2]. - The company plans to focus on its two main brands, Yilian and Aier Doctor, and enhance product lines in sprays, probiotics, and collagen to drive growth [2]. Group 3: Research and Development - The company invested approximately 42 million yuan in R&D in Q1 2025, focusing on new product development and technological breakthroughs across cosmetics, pharmaceuticals, and raw materials [3]. - The company has achieved 12 new patent authorizations and launched 47 new products in the first quarter [3]. Group 4: Pharmaceutical and Raw Material Business - The pharmaceutical segment generated a revenue of 108 million yuan, remaining stable year-on-year, with a gross margin of 54.8% [3]. - The raw materials and additives segment achieved a revenue of 86 million yuan, a 2.4% increase year-on-year, with a gross margin rising nearly 10 percentage points to 39.54% [3].